Cardiology

Further Reductions in Alirocumab Price Needed to Be Considered Cost-Effective




For alirocumab to be considered cost-effective compared with generic ezetimibe, its annual price would have to be reduced to less than $90.

Source link




Related posts

Does elevated RVEDP cause dyspnea ?

Newsemia

Sitting Time, Physical Activity, and Risk of Mortality in Adults

Newsemia

From Intervention to Prevention: Dr. Pierre P. Leimgruber to Join the Heart Attack & Stroke Prevention Center in April

Newsemia

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy